

Development Pipeline & Key Development Projects

May 25, 2009

FY2008 Business Results Briefing

Hotel Metropolitan Edmont

Ken-ichi Yanagisawa

Board Director

Managing Executive Officer

Development Division

□ Development Pipeline Status

□ Key Development Projects

Redefinition of the Global Development Organization

□ Other Development Topics

Development Pipeline Status



田辺三菱製薬

< Domestic >

Changes since October 30, 2008

 : stage up

Metabolism/
Cardiovascular

Immunology

CNS

Others

Domestic

TA-7284
(Diabetes Mellitus)

TA-6666
(Type 2 Diabetes Mellitus)

Cholebine
(Hyperphosphatemia)

MP-435
(Rheumatoid Arthritis)

Phase 1

Cholebine
(Type 2 Diabetes Mellitus)

MP-513
(Type 2 Diabetes Mellitus)

MCC-847
(Allergic Rhinitis)

FTY720
(Multiple Sclerosis)

MP-214 (Schizophrenia)

Phase 2

Maintate
(Chronic Heart Failure)

CNT0148
(Rheumatoid Arthritis)

Pazucross
(Additional dose,
Sepsis/Pneumococcus)

Remicade
(Crohn's disease)

Remicade
(Ulcerative Colitis)

APTA-2217 (COPD)

APTA-2217 (Asthma)

MCC-847 (Asthma)

VG-IH (Myasthenia Gravis)

VG-IH (Systemic Sclerosis)

Modiodal (OSAS)

Radicut (ALS)

MP-424
(Chronic Hepatitis C)

Phase 3

Valixa (Post-transplant
CMV infection)

Remicade
(Ankylosing Spondylitis)

Remicade (Psoriasis)

Remicade
(Additional dose,
Rheumatoid Arthritis)

VG-IH (Hypo-,
Agammaglobulinemia)

VG-IH
(IgG2 deficiency)

VG-IH (Polymyositis,
Dermatomyositis)

Ceredist (Spinocerebellar
Degeneration, OD tablet)

TA-8317/ACREF
(Breakthrough
Cancer Pain)

filed

 : stage down

Neuart
(Toxemia of Pregnancy)

Application withdrawn

Anplag
(Cerebral Infarction)

Development terminated


< Overseas > In-house developments, licensed products



Changes since October 30, 2008

田辺三菱製薬

 : stage up




* to be filed


Key Development Projects



田辺三菱製薬




Global Development Projects (CKD)




SHPT: Secondary Hyperparathyroidism

In-house Global Developments

Early Establishment of a Global development Platform



(Target NDA)



CKD : Chronic Kidney Disease
SHPT: Secondary Hyperparathyroidism

MTPC : Mitsubishi Tanabe Pharma Corp.
MPA : Mitsubishi Pharma America Inc.
MPE : Mitsubishi Pharma Europe Ltd.
MPBJ : Mitsubishi Pharma Research & Development Co. Ltd. (Beijing)

Redefinition of the Global Development Organization




1. Re-organization towards global development
(Executing a new paradigm shift from April 2009)
2. Global and regional project team structures in response to development regions
3. Development Governance Structure
4. Globalization of the Development Process

To-be Organization

Governance and coordination

- Development strategy
- Portfolio management
- Global budget management
- Global resource management
- Global development coordination
- Strategic decision making coordination



Regional development

- Development execution
- Regional budget management
- Regional resource management
- Practical decision making (Resource changes, CRO contracts etc.)

Improving Development Speed

3. Preparation of multi national clinical trials

2. Obtain approval in Asia

1. Accelerate filing and approval in Japan

Preparation and execution of Asian Development

Candidate Therapeutic Areas in Asia

CNS

Diabetes

Hepatic disease


Others

Asia

Developments in Diabetes



田辺三菱製薬



Pipeline

Diabetes pipelines for the various mechanisms of action

Product	Mechanism of Action	Development Region and Status		
MP-513	DPP4 inhibitor	Japan	P2	In House
		Overseas	P1	Alliance
TA-7284	SGLT2 inhibitor	Japan	P1	In House
		Overseas	P2	Alliance
MCI-196	Bile acid signal regulation	Japan	P2	In House
		Overseas	P2 Preparation	In House
New Compound	New MOA			

Developments in Stroke

Phase 1

MP-124

Stroke
(US)

Phase 2


MCI-186

Stroke
(EU, In preparation)

Stroke development currently being conducted overseas.

MCI-186, P2 preparation

Clinical trials in preparation, EU




PARP Inhibitor, P1

- Clinical trials in the US and Canada
- Inhibits excessive PARP activation due to ischemic DNA damage, suppressing cell death

Maximizing the Value of Remicade


¥100M



MP-424: Developments in Chronic Hepatitis C



Final Results of the PROVE1 Study (SVR24)




424 : MP-424
PEG : peg-interferon
RBV : Ribavirin

EASL 2008 PROVE1, oral presentation, April 2008
JG McHutchison et.al

MP-424: Chronic Hepatitis C




Dynamics of HCV-RNA with Chronic Hepatitis C



MP-424: Development Schedule



田辺三菱製薬



FTY720: Developments in Multiple Sclerosis



FTY720 overseas P3 results (one year study)

American Academy of
Neurology
Novartis: Apr. 29th, 2009

Results


- Relapse rate with FTY720 was lower than with interferon beta-1a

Serious Adverse Events (<1.5%)

- Bradycardia, atrioventricular block 0.8-1.4%
- Macular edema 0.9%
- Infection (Appendicitis, Herpes viral infections) 0.5%
- Skin Cancer (Basal cell carcinoma, Malignant melanoma) 0.7%
- Breast Cancer 0.5%
- Dyspnea 0.5%

Development Status

- US & EU: Filing planned for the end of 2009
(Novartis press release, April 2009)
- Japan: P2



Cautionary Statement

Statements contained in this presentation are based on a number of assumptions and beliefs in light of information currently available to the management of the company and is subject to significant risks and uncertainties.